Array Biopharma beats analyst expectations despite Q3 loss
BOULDER — Array Biopharma Inc. (Nasdaq: ARRY) beat analyst expectations for its third quarter earnings by 11 cents, despite posting a loss of 11 cents per share.
Array, a Boulder-based biotech company, had a net loss of nearly $22.9 million, an improvement on the same period the year prior, when the net loss was $35.3 million.
Revenue was $66 million, which grew 99 percent year-over-year and beat expectations by $34.7 million.
SPONSORED CONTENT
Business Cares: May 2024
As Mental Health Awareness Month unfolds in Colorado, it serves as a reminder of the collective responsibility to prioritize mental well-being.
Array added that its new drug applications for the combination of its drugs encorafenib and binimetinib to treat patients with advanced or metastatic melanoma are under review with a target action date of June 30.
BOULDER — Array Biopharma Inc. (Nasdaq: ARRY) beat analyst expectations for its third quarter earnings by 11 cents, despite posting a loss of 11 cents per share.
Array, a Boulder-based biotech company, had a net loss of nearly $22.9 million, an improvement on the same period the year prior, when the net loss was $35.3 million.
Revenue was $66 million, which grew 99 percent year-over-year and beat expectations by $34.7 million.
Array added that its new drug applications for the combination of its drugs encorafenib and binimetinib to treat patients with advanced or…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
